The Role of Inheritance and the Care of Children
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Ectodermal Dysplasias: a New Clinical-Genetic Classification
J Med Genet 2001;38:579–585 579 Ectodermal dysplasias: a new clinical-genetic J Med Genet: first published as 10.1136/jmg.38.9.579 on 1 September 2001. Downloaded from classification Manuela Priolo, Carmelo Laganà Abstract many case reports and personal communica- The ectodermal dysplasias (EDs) are a tions in their listing of EDs, as well as large and complex nosological group of conditions traditionally classified under other diseases, first described by Thurnam in headings, for example dyskeratosis congenita11 1848. In the last 10 years more than 170 and keratitis-ichthyosis-deafness (KID) syn- diVerent pathological clinical conditions drome12 (poikiloderma and immune defect have been recognised and defined as EDs, diseases and erythrokeratodermas, respec- all sharing in common anomalies of the tively). Further, they did not appear to hair, teeth, nails, and sweat glands. Many consider variability of expression and may are associated with anomalies in other have reported, as distinct diseases, conditions organs and systems and, in some condi- that reflect variable expression of the same tions, with mental retardation. pathological entity. Moreover, they included The anomalies aVecting the epidermis pathological conditions which, in our opinion, and epidermal appendages are extremely do not strictly fulfil the diagnostic criteria for variable and clinical overlap is present EDs, such as conditions with secondary among the majority of EDs. Most EDs are involvement of epidermal derivatives rather defined by particular clinical signs (for than a primary defect. We abandoned the 1-2- example, eyelid adhesion in AEC syn- 3-4 designation of EDs, because we believe drome, ectrodactyly in EEC). -
Bilateral Lower Extremity Hyperkeratotic Plaques: a Case Report of Ichthyosis Vulgaris
Faculty & Staff Scholarship 2015 Bilateral lower extremity hyperkeratotic plaques: a case report of ichthyosis vulgaris Hayley Leight Zachary Zinn Omid Jalali Follow this and additional works at: https://researchrepository.wvu.edu/faculty_publications Clinical, Cosmetic and Investigational Dermatology Dovepress open access to scientific and medical research Open Access Full Text Article CASE REPORT Bilateral lower extremity hyperkeratotic plaques: a case report of ichthyosis vulgaris Hayley Leight Abstract: Here, we report a case of a middle-aged woman presenting with severe, long-standing, Zachary Zinn hyperkeratotic plaques of the lower extremities unrelieved by over-the-counter medications. Omid Jalali Initial history and clinical findings were suggestive of an inherited ichthyosis. Ichthyoses are genetic disorders characterized by dry scaly skin and altered skin-barrier function. A diagnosis Department of Dermatology, West Virginia University, of ichthyosis vulgaris was confirmed by histopathology. Etiology, prevalence, and treatment Morgantown, WV, USA options are discussed. Keywords: filaggrin gene, FLG, profilaggrin, keratohyalin granules, hyperkeratosis Introduction For personal use only. Inherited ichthyoses are a diverse group of genetic disorders characterized by dry, scaly skin; hyperkeratosis; and altered skin-barrier function. While these disorders of cutaneous keratinization are multifaceted and varying in etiology, disruption in the stratum corneum with generalized scaling is common to all.1–4 Although not entirely known -
Blueprint Genetics Ectodermal Dysplasia Panel
Ectodermal Dysplasia Panel Test code: DE0401 Is a 25 gene panel that includes assessment of non-coding variants. Is ideal for patients with a clinical suspicion of ectodermal dysplasia (hidrotic or hypohidrotic) or Ellis-van Creveld syndrome. About Ectodermal Dysplasia Ectodermal Dysplasia (ED) is a group of closely related conditions of which more than 150 different syndromes have been identified. EDs affects the development or function of teeth, hair, nails and sweat glands. ED may present as isolated or as part of a syndromic disease and is commonly subtyped according to sweating ability. The clinical features of the X-linked and autosomal forms of hypohidrotic ectodermal dysplasia (HED) can be indistinguishable and many of the involved genes may lead to phenotypically distinct outcomes depending on number of defective alleles. The most common EDs are hypohidrotic ED and hydrotic ED. X-linked hypohidrotic ectodermal dysplasia (HED) is caused by EDA mutations and explain 75%-95% of familial HED and 50% of sporadic cases. HED is characterized by three cardinal features: hypotrichosis (sparse, slow-growing hair and sparse/missing eyebrows), reduced sweating and hypodontia (absence or small teeth). Reduced sweating poses risk for episodes of hyperthermia. Female carriers may have some degree of hypodontia and mild hypotrichosis. Isolated dental phenotypes have also been described. Mutations in WNT10A have been reported in up to 9% of individuals with HED and in 25% of individuals with HED who do not have defective EDA. Approximately 50% of individuals with heterozygous WNT10A mutation have HED and the most consistent clinical feature is severe oligodontia of permanent teeth. -
MECHANISMS in ENDOCRINOLOGY: Novel Genetic Causes of Short Stature
J M Wit and others Genetics of short stature 174:4 R145–R173 Review MECHANISMS IN ENDOCRINOLOGY Novel genetic causes of short stature 1 1 2 2 Jan M Wit , Wilma Oostdijk , Monique Losekoot , Hermine A van Duyvenvoorde , Correspondence Claudia A L Ruivenkamp2 and Sarina G Kant2 should be addressed to J M Wit Departments of 1Paediatrics and 2Clinical Genetics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, Email The Netherlands [email protected] Abstract The fast technological development, particularly single nucleotide polymorphism array, array-comparative genomic hybridization, and whole exome sequencing, has led to the discovery of many novel genetic causes of growth failure. In this review we discuss a selection of these, according to a diagnostic classification centred on the epiphyseal growth plate. We successively discuss disorders in hormone signalling, paracrine factors, matrix molecules, intracellular pathways, and fundamental cellular processes, followed by chromosomal aberrations including copy number variants (CNVs) and imprinting disorders associated with short stature. Many novel causes of GH deficiency (GHD) as part of combined pituitary hormone deficiency have been uncovered. The most frequent genetic causes of isolated GHD are GH1 and GHRHR defects, but several novel causes have recently been found, such as GHSR, RNPC3, and IFT172 mutations. Besides well-defined causes of GH insensitivity (GHR, STAT5B, IGFALS, IGF1 defects), disorders of NFkB signalling, STAT3 and IGF2 have recently been discovered. Heterozygous IGF1R defects are a relatively frequent cause of prenatal and postnatal growth retardation. TRHA mutations cause a syndromic form of short stature with elevated T3/T4 ratio. Disorders of signalling of various paracrine factors (FGFs, BMPs, WNTs, PTHrP/IHH, and CNP/NPR2) or genetic defects affecting cartilage extracellular matrix usually cause disproportionate short stature. -
Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency
Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD, David A. Khan, MD, Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD, David I. Bernstein, MD, Joann Blessing-Moore, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Chief Editor: Francisco A. Bonilla, MD, PhD Co-Editor: David A. Khan, MD Members of the Joint Task Force on Practice Parameters: David I. Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Primary Immunodeficiency Workgroup: Chairman: Francisco A. Bonilla, MD, PhD Members: Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/ These parameters were developed by the Joint Task Force on Practice Parameters, representing Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/ the American Academy of Allergy, Asthma & Immunology; the American College of Novartis and Merck. -
Significant Absorption of Topical Tacrolimus in 3 Patients with Netherton Syndrome
OBSERVATION Significant Absorption of Topical Tacrolimus in 3 Patients With Netherton Syndrome Angel Allen, MD; Elaine Siegfried, MD; Robert Silverman, MD; Mary L. Williams, MD; Peter M. Elias, MD; Sarolta K. Szabo, MD; Neil J. Korman, MD, PhD Background: Tacrolimus is a macrolide immunosup- limus in organ transplant recipients. None of these pressant approved in oral and intravenous formulations patients developed signs or symptoms of toxic effects of for primary immunosuppression in liver and kidney trans- tacrolimus. plantation. Topical 0.1% tacrolimus ointment has re- cently been shown to be effective in atopic dermatitis for Conclusions: Patients with Netherton syndrome have children as young as 2 years of age, with minimal sys- a skin barrier dysfunction that puts them at risk for in- temic absorption. We describe 3 patients treated with topi- creased percutaneous absorption. The Food and Drug Ad- cal 0.1% tacrolimus who developed significant systemic ministration recently approved 0.1% tacrolimus oint- absorption. ment for the treatment of atopic dermatitis. Children with Netherton syndrome may be misdiagnosed as having Observation: Three patients previously diagnosed as atopic dermatitis. These children are at risk for marked having Netherton syndrome were treated at different cen- systemic absorption and associated toxic effects. If topi- ters with 0.1% tacrolimus ointment twice daily. Two pa- cal tacrolimus is used in this setting, monitoring of se- tients showed dramatic improvement. All patients were rum tacrolimus levels is essential. found to have tacrolimus blood levels within or above the established therapeutic trough range for oral tacro- Arch Dermatol. 2001;137:747-750 ETHERTON syndrome is taneous absorption of the drug, with serum an autosomal recessive levels well above the therapeutic range. -
Chronic Diarrhea in an Adolescent Girl with a Genetic Skin Condition
PHOTO CHALLENGE Chronic Diarrhea in an Adolescent Girl With a Genetic Skin Condition Lucia Liao, BS; Andrea Zaenglein, MD; Galen T. Foulke, MD A 17-year-old adolescent girl visited our clinic to establish care for her genetic skin condition. She exhibited red scaly plaques and patches over much of the body surface area consistent with atopic dermatitis but also had areas on the trunk with serpiginous red plaques with scale on the leading and trailingcopy edges. She also noted fragile hair with sparse eyebrows. The patient reported that she had experienced chronic diarrhea and abdominal pain since childhood. She asked if it couldnot be related to her genetic condition. WHAT’S THE DIAGNOSIS? a. dyskeratosis follicularis (Darier disease) b. elastosis perforans serpiginosa Doc. erythema marginatum d. Netherton syndrome e. subacute cutaneous lupus erythematosus PLEASE TURN TO PAGE E19 FOR THE DIAGNOSIS CUTIS Ms. Liao is from Pennsylvania State University College of Medicine, Hershey. Drs. Zaenglein and Foulke are from the Department of Dermatology, Pennsylvania State Medical Center, Hershey. Dr. Zaengelin also is from the Department of Pediatrics. The authors report no conflict of interest. Correspondence: Galen T. Foulke, MD, 500 University Dr HU14, Hershey, PA 17033 ([email protected]). E18 I CUTIS® WWW.MDEDGE.COM/DERMATOLOGY Copyright Cutis 2020. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher. PHOTO CHALLENGE DISCUSSION THE DIAGNOSIS: Netherton Syndrome -
Proceedings of the 16Th Annual Meeting of the Society for Pediatric Dermatoiogy
SPECIAL ARTICLE Pediatric Dermatology Vol. 9 No. 1 66-76 Proceedings of the 16th Annual Meeting of the Society for Pediatric Dermatoiogy WiUiamsburg, Virginia June 3a-July 3, 1991 Eleanor £. Sahn, M.D. Medical University of South Carolina Charleston, South Carolina A. Howiand Hartley, M.D. Children's Hospital National Medical Center Washington, D.C. Stephen Gellis, M.D. Children's Hospital Medical Center Boston, Massachusetts James E. Rasmussen, M.D. University of Michigan Medical Center Ann Arbor, Michigan Monday, July 1, 1991 ture by the newspaper account he received, dated December 17, 1799, telling of General George Dr. Alfred T. Lane (Stanford University) orga- Washington's death. We learn the story of General nized the sixteenth annual meeting of the Society Washington's rapid demise, probably from bacterial for Pediatric Dermatology, held in Wiliiamsburg, infection, hastened by the medical treatments of the Virgitiia. The seventh annual Sidney Hurwitz Lec- day, including frequent and copious blood letting. ture was delivered by Dr. Rona M. MacKie (Uni- There was a current saying, "more people died an- versity of Glasgow) on "Melanoma: Risk Factors in nually from lancets than from swords." Dysplastic Nevus Syndrome." President Anne Lucky (Cincinnati, Ohio) welcomed the society MELANOMA: RISK FACTORS AND members to Wiliiamsburg and introduced the first DYSPLASTIC NEVUS SYNDROME speaker. Dr. Rona MacKie first discussed risk factors in mel- anoma, citing several large case control studies car- COLONIAL MEDICINE ried out in western Canada, Scotland, Scandinavia, Dr. Tor A. Shwayder (Henry Ford Hospital) pre- and Germany. The frequency of melanoma has dou- sented a delightful and professional "Character In- bled each decade in Scandinavia, the United King- terpreter Portrayal of Iseiac Shwayder, Medical dom, and Germany. -
CORPORATE PRESENTATION Q3 2020 Forward-Looking Statements
Medicines for Rare Diseases – A Gene Therapy Company CORPORATE PRESENTATION Q3 2020 Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. Any statements in this presentation about future expectations, plans and prospects for Krystal Biotech, Inc. (the “Company”), including but not limited to statements about the development of the Company’s product candidates, such as the future development or commercialization of B-VEC, KB105 and the Company’s other product candidates; conduct and timelines of clinical trials, the clinical utility of B-VEC, KB105 and the Company’s other product candidates; plans for and timing of the review of regulatory filings, efforts to bring B-VEC, KB105 and the Company’s other product candidates to market; the market opportunity for and the potential market acceptance of B-VEC, KB105 and the Company’s other product candidates, the development of B-VEC, KB105 and the Company’s other product candidates for additional indications; the development of additional formulations of B-VEC, KB105 and the Company’s other product candidates; plans to pursue research and development of other product candidates, the sufficiency of the Company’s existing cash resources; and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the content and timing of decisions made by the U.S. -
Mutation and Expression of Abca12in Keratosis Pilaris and Nevus
MOLECULAR MEDICINE REPORTS 18: 3153-3158, 2018 Mutation and expression of ABCA12 in keratosis pilaris and nevus comedonicus FEN LIU1,2*, YAO YANG1,3*, YAN ZHENG1,3, YAN-HUA LIANG1,3 and KANG ZENG1 1Department of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515; 2Department of Histology and Embryology, Institute of Neuroscience, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035; 3Department of Dermatology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong 518100, P.R. China Received June 22, 2017; Accepted April 17, 2018 DOI: 10.3892/mmr.2018.9342 Abstract. Keratosis pilaris (KP) and nevus comedonicus Introduction (NC) are congenital keratinized dermatoses; however, the exact etiology of these two diseases is unclear. The objective Keratosis pilaris (KP; OMIM #604093), also known as of the present study was to identify the disease-causing genes lichen pilaris, is a benign genodermatosis that is estimated and their association with functional alterations in the devel- to effect ~40% of the population (1). KP is characterized by opment of KP and NC. Peripheral blood samples of one KP the presence of symmetric, asymptomatic and grouped kera- family, two NC families and 100 unrelated healthy controls totic follicular papules with varying degrees of perifollicular were collected. The genomic sequences of 147 genes associ- erythema. KP lesions often involve the proximal and extended ated with 143 genetic skin diseases were initially analyzed parts of extremities, the cheeks and the buttocks (2). Cases from the KP proband using a custom-designed GeneChip. A may be generalized or unilateral (2). Most patients develop KP novel heterozygous missense mutation in the ATP-binding in their childhood, with a peak in incidence during adoles- cassette sub-family A member 12 (ABCA12) gene, designated cence (3). -
Genodermatoses
GENODERMATOSES Genodermatoses What’s new? Nigel P Burrows C Filaggrin mutations underlie ichthyosis vulgaris and are a risk factor for atopy including eczema, allergic sensitization, asthma, allergic rhinitis and peanut allergy Abstract C A new classification and nomenclature for ichthyoses was Genetic skin diseases encompass a spectrum from the common to the published in 2009, peeling skin syndromes which may be rare. It is important for the clinician to be alert to the possibility that confused for the milder subtypes of epidermolysis bullosa are the patient may be presenting for the first time with one or more features distinct genetic entities of a genetic disease so that appropriate investigation and counselling can C Emerging evidence that pseudoxanthoma elasticum is a meta- take place. Recent discoveries have helped the understanding of many of bolic disorder resulting in calcification of elastic fibres these disorders. A few common and important genodermatoses are high- C Mammalian target of rapamycin (mTOR) inhibitor therapies are lighted in this article. showing promise in tuberous sclerosis complex C Vascular anomalies on the skin may be the presenting feature of Keywords cancer syndromes; collagen; epidermolysis bullosa; filaggrin; inherited syndromes genodermatoses; ichthyosis; keratinization; pseudoxanthoma elasticum; vascular anomalies X-linked recessive ichthyosis In 75% of cases of X-linked recessive ichthyosis (XLRI) (Figure 1), scaling is present in the first week of life and tends to progress into adolescence. In contrast to IV, the flexures may be Genetic skin diseases encompass a spectrum from the common involved. A third of cases are associated with a prolonged labour. (e.g. atopic eczema) to the rare (e.g. -
Ichthyosis Vulgaris a Case Report and Review of Literature Sarah E
CASE REPORT Ichthyosis Vulgaris A Case Report and Review of Literature Sarah E. Mertz, Thea D. Nguyen, Lori A. Spies chthyosis vulgaris (IV) is a hereditary skin condi- removal surgery. By patient report, the lesions had been tion characterized by an accumulation of cells in present since childhood but progressively worsened over the horny layer that manifests as xerotic, plate- the past few years because of a lack of skin care routine. As like scales. It is most prominent on the extensor is typical in IV, there was a history of improvement of surfaces of the extremities, back, abdomen, and symptoms in warmer months of the summer. Comorbidities legs and exhibits palmar hyperlinearity (Takeichi & to the long-standing IV and cognitive disability include IAkiyama, 2016). If not properly treated, this build up hypertension and obesity. There was no personal history of can cause difficulty in patient care and a decrease in the skin cancer, and the patient was not able to provide details of quality of life of those afflicted with this condition. his family history. On physical examination, significant and There are more than 20 types of ichthyosis to include pertinent findings include diffuse symmetric, thick, hyper- epidermolytic ichthyosis, congential reticular ichthyosiform keratotic, light-gray, fish-scaled plaques with fissures prom- erythroderma, and lamellar ichthyosis, with IV being the inent on the dorsal and ventral surfaces of the bilateral upper most common type of hereditary nonsyndromic ichthyosis extremities including arms, forearms, dorsal hands, and and characterized as a reduction of keratohyalin granules posterior neck and fine, scaly, erythematous areas of or a granular layer absence (Takeichi & Akiyama, 2016).